Printer Friendly

LEICK TO LEAD LECTEC DRUG DELIVERY PRODUCTS EXPANSION

 LEICK TO LEAD LECTEC DRUG DELIVERY PRODUCTS EXPANSION
 MINNETONKA, Minn., April 22 /PRNewswire/ -- LecTec Corporation today


announced the addition of Robert T. Leick as director, sales and marketing, Therapeutic Products Group. This addition underscores LecTec's expansion into the transdermal drug delivery field.
 The therapeutic products group of LecTec researches, develops and manufactures non-invasive skin contact drug delivery products for prescription or over-the-counter sales. LecTec has established and previously announced strategic alliances with prominent pharmaceutical and drug marketing companies.
 According to Dr. Tom Brunelle, senior vice president, "Bob Leick brings to our company over 23 years of pharmaceutical marketing expertise. His knowledge of this key market and technology will help to accelerate our growth in transdermal drug delivery."
 Leick was associated with Bristol-Myers Squibb Company since 1968 in various sales and marketing positions. Leick's management activities included the Bristol-Myers U.S. Pharmaceutical and Mead Johnson Nutritional Groups.
 LecTec Corporation develops, manufactures and markets non-invasive medical products for use worldwide. Among the company's products are diagnostic and long-term monitoring cardiac electrodes, medical tapes and transdermal drug delivery systems. LecTec is traded on NASDAQ under the symbol LECT.
 -0- 4/22/92
 /CONTACT: Jan Jachimowicz of LecTec, 612-933-2291/
 (LECT) CO: LecTec Corporation ST: Minnesota IN: MTC SU:


DS -- MN004 -- 1146 04/22/92 10:13 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 22, 1992
Words:213
Previous Article:SIERRA TUCSON COMPANIES INC. ANNOUNCES UNAUDITED FIRST QUARTER RESULTS
Next Article:NVIEW FIRST QUARTER EARNINGS UP SIGNIFICANTLY


Related Articles
LECTEC BOARD APPROVES ADDED EMPHASIS ON TRANSDERMAL BUSINESS DEVELOPMENT; CITES SIGNIFICANT OPPORTUNITIES
LECTEC REVIEWING POSSIBLE PATENT INFRINGEMENTS OF TRANSDERMAL NICOTINE TECHNOLOGY
UNIVERSITY OF MINNESOTA, LECTEC AGREE TO DEVELOP NICOTINE-FREE SMOKING CESSATION TREATMENT
LECTEC BOARD INTENSIFIES FUNDING FOR TRANSDERMAL PATCH DEVELOPMENT; TO TREAT SMOKERS, CANCER PATIENTS, OTHERS
LECTEC SMOKING CESSATION PATCH DEVELOPMENT PROGRESSES; PATENT PENDING
LECTEC THIRD QUARTER RESULTS REFLECT INCREASED INVESTMENT IN NEW PRODUCT DEVELOPMENT
LECTEC TO LAUNCH NEW PRODUCT FOR TREATMENT OF BED SORES AND OTHER CHRONIC WOUNDS
LECTEC ANNOUNCES FIRST STOCK DIVIDEND IN COMPANY HISTORY; CITES CONFIDENCE FOR THE FUTURE AND BUSINESS EXPANSION
LECTEC AND UNIVERSITY OF MINNESOTA PURSUE SAFER ALTERNATIVE TO NICOTINE FOR SMOKING CESSATION PATCHES
NATUS AND LECTEC SIGN INVESTMENT AND DEVELOPMENT PACTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters